ProMetic Life Sciences Inc. Jumps More Than 21% on FDA Designation

ProMetic Life Sciences Inc.’s (TSX:PLI) plasminogen drug Ryplazimä has been granted a “Rare Pediatric Disease” designation by the U.S. Food and Drug Administration, renewing investor interest in the Canadian bio-pharmaceutical company.

The Motley Fool

Today, shares of ProMetic Life Sciences Inc.(TSX:PLI) jumped more than 21% in early morning trading on news that its plasminogen drug, Ryplazimä, has been granted a “Rare Pediatric Disease” designation by the U.S. Food and Drug Administration (FDA), a drug which I covered in late December amid the beginning of a slide which has continued for ProMetic since the beginning of the year.

My thesis at the time was that the pipeline of drugs for ProMetic was not being accurately priced by the market, with the probability of success for the company’s Ryplazimä not fully appreciated by the market at the time. Despite the company’s stock price dipping another 35% since my initial article on the bio-pharmaceutical company, this most recent rebound following news of the FDA designation has sent ProMetic’s share price abruptly higher, reflecting much of the positive market sentiment stemming from the new designation.

The FDA has now provided three designations for Ryplazimä; in addition to a Rare Pediatric Disease designation, the drug has also received Orphan Drug status as well as Fast Track status — designations which highlight the importance of the drug and the current unmet need in the market for plasminogen treatments such as Ryplazimä.

If Ryplazimä indeed receives final FDA approval, the drug is in line to receive a rare pediatric disease priority voucher, which can be used to accelerate the review of an existing drug within the company’s pipeline or be sold off to a third party for a tidy profit. This is a rare asset handed out only in cases of significant unmet need: a scenario which has played out in favour of ProMetic’s Ryplazimä drug.

ProMetic’s chief executive officer Pierre Laurin spoke to the recent FDA announcement in a press release:

“We are pleased that RyplazimäTM has received this pediatric designation from the FDA. In addition to Ryplazimä’sTM orphan drug status, this designation represents another validation of the approach we have taken regarding our plasminogen’s clinical program…The pediatric designation also provides an important incentive for ProMetic to continue developing therapies addressing unmet medical needs for children with rare diseases. We look forward to continue to work closely with the FDA to bringing this innovative therapy to patients suffering from plasminogen deficiency.”

Bottom line

This is yet another step in the right direction for ProMetic — a company with a significant amount of promise in the Canadian bio-pharmaceutical space, one which has been hit hard in recent years. I will be watching this company closely over the coming weeks and months as new developments continue to roll in.

Stay Foolish, my friends.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Chris MacDonald has no position in any stocks mentioned in this article.

More on Investing

Person Computer 1
Investing

Trump Tariffs: You Won’t Believe What Top Stock Is Below Its 52-Week Low

The stock market has gotten off to a very different start to the year than most investors might have imagined.…

Read more »

Blocks conceptualizing Canada's Tax Free Savings Account
Dividend Stocks

Where to Invest Your $7,000 TFSA Contribution for Long-Term Gains

Whether it's infrastructure, real estate or tech, these three stocks offer a promising addition to your TFSA.

Read more »

Dam of hydroelectric power plant in Canadian Rockies
Dividend Stocks

3 Low-Volatility TSX Stocks for Smoother Returns

Find stability in an era of tariff-induced uncertainty with Hydro One and two other low-volatility Canadian stocks

Read more »

coins jump into piggy bank
Dividend Stocks

Better Dividend Stock: Canadian Tire vs. CT REIT? 

Both Canadian Tire and CT REIT are good dividend stocks. However, which is a better investment depends on your financial…

Read more »

Senior uses a laptop computer
Dividend Stocks

Why Canadian Dividend Stocks Are Still a Smart Buy in 2025

Here are some tax-related reasons why investors should continue to buy Canadian dividend stocks.

Read more »

monthly desk calendar
Dividend Stocks

3 Monthly Dividend Stocks to Buy and Hold Forever

These three dividend stocks offer monthly income and so much more for investors seeking growth in their portfolio.

Read more »

up arrow on wooden blocks
Tech Stocks

3 Brilliant Growth Stocks to Buy Now and Hold for the Long Term

If you have a long-term horizon to invest, consider investigating these three growth stocks.

Read more »

TFSA (Tax free savings account) acronym on wooden cubes on the background of stacks of coins
Dividend Stocks

3 Canadian Stocks to Consider Adding to Your TFSA in 2025

Canadian dividend stocks like Altagas are a prime candidate for your TFSA due to their attractive valuations and dividend yields.

Read more »